News

Investigative Immunotherapy ImmCelz Shows Promise in Mice

Creative Medical Technology Holdings has extended the applications of its investigational “regenerative immunotherapy” ImmCelz to include Parkinson’s disease, after seeing positive preclinical data from a mouse model of the disease, according to a company press release. ImmCelz inhibited the onset of Parkinson’s symptoms in a mouse model of the…

COVID-19 Poses Greater Risk to Hospitalized Patients

People with Parkinson’s disease who are hospitalized with COVID-19 may have a greater risk for more severe infections and higher mortality, according to a recent study of German hospital records. The study, “Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson’s Disease in Germany,” was published…

Study Ties Swallowing Abilities to Disease Progression

Swallowing difficulties seem to be associated with progression of Parkinson’s disease, a study has found. Researchers found that high doses of levodopa can increase xerostomia — or dry mouth — and negatively affect the oral environment. Moreover, people with Parkinson’s seem to be unaware of their swallowing difficulties, which could lead to…

Low-dose Sargramostim Shows Promise in Small Early Trial

Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical trial of people with Parkinson’s disease. The results “provide the basis for larger scale assessments to determine clinical efficacy of a reduced sargramostim regimen within the [Parkinson’s] population,” according…

Korean Study Ties Air Pollution to Developing Parkinson’s

Nitrogen dioxide (NO2) is associated significantly with a higher risk for developing Parkinson’s disease, according to a recent study from Korea. The finding reinforces previous research showing a potential link between air pollution and Parkinson’s. The results also prompted researchers to suggest that better air pollution regulations might lower…